DL-Tartaric Acid
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global CD47 (IAP) Market Research Report 2023
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 CD47 Monoclonal Antibody
1.2.3 CD47 Double Antibody
1.2.4 CD47 Fusion Protein
1.3 Market by Application
1.3.1 Global CD47 (IAP) Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Solid Tumor
1.3.3 Lymphoma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global CD47 (IAP) Market Perspective (2017-2028)
2.2 CD47 (IAP) Growth Trends by Region
2.2.1 CD47 (IAP) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 CD47 (IAP) Historic Market Size by Region (2017-2022)
2.2.3 CD47 (IAP) Forecasted Market Size by Region (2023-2028)
2.3 CD47 (IAP) Market Dynamics
2.3.1 CD47 (IAP) Industry Trends
2.3.2 CD47 (IAP) Market Drivers
2.3.3 CD47 (IAP) Market Challenges
2.3.4 CD47 (IAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD47 (IAP) Players by Revenue
3.1.1 Global Top CD47 (IAP) Players by Revenue (2017-2022)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2017-2022)
3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD47 (IAP) Revenue
3.4 Global CD47 (IAP) Market Concentration Ratio
3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2021
3.5 CD47 (IAP) Key Players Head office and Area Served
3.6 Key Players CD47 (IAP) Product Solution and Service
3.7 Date of Enter into CD47 (IAP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD47 (IAP) Breakdown Data by Type
4.1 Global CD47 (IAP) Historic Market Size by Type (2017-2022)
4.2 Global CD47 (IAP) Forecasted Market Size by Type (2023-2028)
5 CD47 (IAP) Breakdown Data by Application
5.1 Global CD47 (IAP) Historic Market Size by Application (2017-2022)
5.2 Global CD47 (IAP) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America CD47 (IAP) Market Size (2017-2028)
6.2 North America CD47 (IAP) Market Size by Country (2017-2022)
6.3 North America CD47 (IAP) Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe CD47 (IAP) Market Size (2017-2028)
7.2 Europe CD47 (IAP) Market Size by Country (2017-2022)
7.3 Europe CD47 (IAP) Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD47 (IAP) Market Size (2017-2028)
8.2 Asia-Pacific CD47 (IAP) Market Size by Country (2017-2022)
8.3 Asia-Pacific CD47 (IAP) Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America CD47 (IAP) Market Size (2017-2028)
9.2 Latin America CD47 (IAP) Market Size by Country (2017-2022)
9.3 Latin America CD47 (IAP) Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD47 (IAP) Market Size (2017-2028)
10.2 Middle East & Africa CD47 (IAP) Market Size by Country (2017-2022)
10.3 Middle East & Africa CD47 (IAP) Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Detail
11.1.2 Gilead Business Overview
11.1.3 Gilead CD47 (IAP) Introduction
11.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
11.1.5 Gilead Recent Development
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Detail
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics CD47 (IAP) Introduction
11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
11.2.5 Innovent Biologics Recent Development
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Detail
11.3.2 Akeso, Inc Business Overview
11.3.3 Akeso, Inc CD47 (IAP) Introduction
11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
11.3.5 Akeso, Inc Recent Development
11.4 Arch Oncology
11.4.1 Arch Oncology Company Detail
11.4.2 Arch Oncology Business Overview
11.4.3 Arch Oncology CD47 (IAP) Introduction
11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.4.5 Arch Oncology Recent Development
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Detail
11.5.2 ImmuneOncia Therapeutics Business Overview
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.5.5 ImmuneOncia Therapeutics Recent Development
11.6 I-MAB
11.6.1 I-MAB Company Detail
11.6.2 I-MAB Business Overview
11.6.3 I-MAB CD47 (IAP) Introduction
11.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
11.6.5 I-MAB Recent Development
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Detail
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.7.5 Sorrento Therapeutics Recent Development
11.8 Zai Lab
11.8.1 Zai Lab Company Detail
11.8.2 Zai Lab Business Overview
11.8.3 Zai Lab CD47 (IAP) Introduction
11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
11.8.5 Zai Lab Recent Development
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Detail
11.9.2 ImmuneOnco Business Overview
11.9.3 ImmuneOnco CD47 (IAP) Introduction
11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
11.9.5 ImmuneOnco Recent Development
11.10 Hengrui
11.10.1 Hengrui Company Detail
11.10.2 Hengrui Business Overview
11.10.3 Hengrui CD47 (IAP) Introduction
11.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
11.10.5 Hengrui Recent Development
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Detail
11.11.2 Beijing Mab-works Business Overview
11.11.3 Beijing Mab-works CD47 (IAP) Introduction
11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
11.11.5 Beijing Mab-works Recent Development
11.12 Hanxbio
11.12.1 Hanxbio Company Detail
11.12.2 Hanxbio Business Overview
11.12.3 Hanxbio CD47 (IAP) Introduction
11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
11.12.5 Hanxbio Recent Development
11.13 ALX Oncology
11.13.1 ALX Oncology Company Detail
11.13.2 ALX Oncology Business Overview
11.13.3 ALX Oncology CD47 (IAP) Introduction
11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.13.5 ALX Oncology Recent Development
11.14 Surface Oncology
11.14.1 Surface Oncology Company Detail
11.14.2 Surface Oncology Business Overview
11.14.3 Surface Oncology CD47 (IAP) Introduction
11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.14.5 Surface Oncology Recent Development
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Detail
11.15.2 TG Therapeutics Business Overview
11.15.3 TG Therapeutics CD47 (IAP) Introduction
11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.15.5 TG Therapeutics Recent Development
11.16 EpicentRx
11.16.1 EpicentRx Company Detail
11.16.2 EpicentRx Business Overview
11.16.3 EpicentRx CD47 (IAP) Introduction
11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
11.16.5 EpicentRx Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global CD47 (IAP) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of CD47 Monoclonal Antibody
Table 3. Key Players of CD47 Double Antibody
Table 4. Key Players of CD47 Fusion Protein
Table 5. Global CD47 (IAP) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global CD47 (IAP) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global CD47 (IAP) Market Share by Region (2017-2022)
Table 9. Global CD47 (IAP) Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global CD47 (IAP) Market Share by Region (2023-2028)
Table 11. CD47 (IAP) Market Trends
Table 12. CD47 (IAP) Market Drivers
Table 13. CD47 (IAP) Market Challenges
Table 14. CD47 (IAP) Market Restraints
Table 15. Global CD47 (IAP) Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global CD47 (IAP) Market Share by Players (2017-2022)
Table 17. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021)
Table 18. Ranking of Global Top CD47 (IAP) Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by CD47 (IAP) Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players CD47 (IAP) Product Solution and Service
Table 22. Date of Enter into CD47 (IAP) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global CD47 (IAP) Revenue Market Share by Type (2017-2022)
Table 26. Global CD47 (IAP) Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global CD47 (IAP) Revenue Market Share by Type (2023-2028)
Table 28. Global CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global CD47 (IAP) Revenue Market Share by Application (2017-2022)
Table 30. Global CD47 (IAP) Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global CD47 (IAP) Revenue Market Share by Application (2023-2028)
Table 32. North America CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific CD47 (IAP) Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 42. Gilead Company Detail
Table 43. Gilead Business Overview
Table 44. Gilead CD47 (IAP) Product
Table 45. Gilead Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 46. Gilead Recent Development
Table 47. Innovent Biologics Company Detail
Table 48. Innovent Biologics Business Overview
Table 49. Innovent Biologics CD47 (IAP) Product
Table 50. Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 51. Innovent Biologics Recent Development
Table 52. Akeso, Inc Company Detail
Table 53. Akeso, Inc Business Overview
Table 54. Akeso, Inc CD47 (IAP) Product
Table 55. Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 56. Akeso, Inc Recent Development
Table 57. Arch Oncology Company Detail
Table 58. Arch Oncology Business Overview
Table 59. Arch Oncology CD47 (IAP) Product
Table 60. Arch Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 61. Arch Oncology Recent Development
Table 62. ImmuneOncia Therapeutics Company Detail
Table 63. ImmuneOncia Therapeutics Business Overview
Table 64. ImmuneOncia Therapeutics CD47 (IAP) Product
Table 65. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 66. ImmuneOncia Therapeutics Recent Development
Table 67. I-MAB Company Detail
Table 68. I-MAB Business Overview
Table 69. I-MAB CD47 (IAP) Product
Table 70. I-MAB Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 71. I-MAB Recent Development
Table 72. Sorrento Therapeutics Company Detail
Table 73. Sorrento Therapeutics Business Overview
Table 74. Sorrento Therapeutics CD47 (IAP) Product
Table 75. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 76. Sorrento Therapeutics Recent Development
Table 77. Zai Lab Company Detail
Table 78. Zai Lab Business Overview
Table 79. Zai Lab CD47 (IAP) Product
Table 80. Zai Lab Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 81. Zai Lab Recent Development
Table 82. ImmuneOnco Company Detail
Table 83. ImmuneOnco Business Overview
Table 84. ImmuneOnco CD47 (IAP) Product
Table 85. ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 86. ImmuneOnco Recent Development
Table 87. Hengrui Company Detail
Table 88. Hengrui Business Overview
Table 89. Hengrui CD47 (IAP) Product
Table 90. Hengrui Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 91. Hengrui Recent Development
Table 92. Beijing Mab-works Company Detail
Table 93. Beijing Mab-works Business Overview
Table 94. Beijing Mab-works CD47 (IAP)Product
Table 95. Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 96. Beijing Mab-works Recent Development
Table 97. Hanxbio Company Detail
Table 98. Hanxbio Business Overview
Table 99. Hanxbio CD47 (IAP)Product
Table 100. Hanxbio Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 101. Hanxbio Recent Development
Table 102. ALX Oncology Company Detail
Table 103. ALX Oncology Business Overview
Table 104. ALX Oncology CD47 (IAP)Product
Table 105. ALX Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 106. ALX Oncology Recent Development
Table 107. Surface Oncology Company Detail
Table 108. Surface Oncology Business Overview
Table 109. Surface Oncology CD47 (IAP)Product
Table 110. Surface Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 111. Surface Oncology Recent Development
Table 112. TG Therapeutics Company Detail
Table 113. TG Therapeutics Business Overview
Table 114. TG Therapeutics CD47 (IAP)Product
Table 115. TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 116. TG Therapeutics Recent Development
Table 117. EpicentRx Company Detail
Table 118. EpicentRx Business Overview
Table 119. EpicentRx CD47 (IAP)Product
Table 120. EpicentRx Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 121. EpicentRx Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD47 (IAP) Market Share by Type: 2021 VS 2028
Figure 2. CD47 Monoclonal Antibody Features
Figure 3. CD47 Double Antibody Features
Figure 4. CD47 Fusion Protein Features
Figure 5. Global CD47 (IAP) Market Share by Application in 2021 & 2028
Figure 6. Solid Tumor Case Studies
Figure 7. Lymphoma Case Studies
Figure 8. Others Case Studies
Figure 9. CD47 (IAP) Report Years Considered
Figure 10. Global CD47 (IAP) Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global CD47 (IAP) Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global CD47 (IAP) Market Share by Region: 2021 VS 2028
Figure 13. Global CD47 (IAP) Market Share by Players in 2021
Figure 14. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by CD47 (IAP) Revenue in 2021
Figure 16. North America CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America CD47 (IAP) Market Share by Country (2017-2028)
Figure 18. United States CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe CD47 (IAP) Market Share by Country (2017-2028)
Figure 22. Germany CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific CD47 (IAP) Market Share by Region (2017-2028)
Figure 30. China CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America CD47 (IAP) Market Share by Country (2017-2028)
Figure 38. Mexico CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa CD47 (IAP) Market Share by Country (2017-2028)
Figure 42. Turkey CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Gilead Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 45. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 46. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 47. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 48. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 49. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 50. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 51. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 52. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 53. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 54. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 55. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 56. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 57. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 58. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 59. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Gilead Innovent Biologics Akeso, Inc Arch Oncology ImmuneOncia Therapeutics I-MAB Sorrento Therapeutics Zai Lab ImmuneOnco Hengrui Beijing Mab-works Hanxbio ALX Oncology Surface Oncology TG Therapeutics EpicentRx